Jaguar Health, Inc. (JAGX)
| Market Cap | 4.19M +8.7% |
| Revenue (ttm) | 27.82M +135.5% |
| Net Income | -52.42M |
| EPS | -155.88 |
| Shares Out | 5.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160,500 |
| Open | 0.8560 |
| Previous Close | 0.8650 |
| Day's Range | 0.7950 - 0.8600 |
| 52-Week Range | 0.7250 - 85.3970 |
| Beta | -0.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About JAGX
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS... [Read more]
Financial Performance
In 2025, Jaguar Health's revenue was $11.51 million, a decrease of -1.52% compared to the previous year's $11.69 million. Losses were -$53.58 million, 39.2% more than in 2024.
Financial StatementsNews
Jaguar Health initiated commercial launch of Neonorm Dog
Jaguar Health (JAGX) announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar’s Neonorm franchise for companion and production animals. “Neonorm Dog is designed to…
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI ...
Jaguar Health Transcript: Investor update
Secured $18 million upfront from a Mytesi out-license, enabling a strategic focus on rare GI diseases. Crofelemer showed up to 48% reduction in parenteral support for MVID, with NDA filing targeted for mid-2027. The intestinal failure market opportunity is estimated at $8 billion.
Jaguar Health Reports Second Quarter 2026 Financials
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced , presentation at ESPGHAN 2026 described additional gro...
Jaguar Health Quarterly report: Q2 2026
Jaguar Health has published its Q2 2026 quarterly earnings report on August 19, 2026.
Jaguar Health Earnings release: Q2 2026
Jaguar Health released its Q2 2026 earnings on August 19, 2026, summarizing the period's financial results.
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ...
Jaguar Health satisfied conditions for receipt of $2M holdback payment
Jaguar Health (JAGX) announced that its wholly-owned subsidiary Napo Pharmaceuticals has satisfied the conditions required to receive payment of the non-dilutive $2M holdback amount from Future Pak re...
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
As announced , Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two com...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Jaguar Health announces findings from surveys of dog owners, vet oncologists
Jaguar Health (JAGX) announced that the findings of exploratory surveys of dog owners and veterinary oncologists support the company’s commercial opportunity for Neonorm Dog, a new extension of Jaguar...
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI ...
Jaguar Health Registration statement: Registration filing
Jaguar Health filed a registration statement on July 24, 2026, providing details about a securities offering with the SEC.
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
Jaguar Health announces additional infant to receive crofelemer powder
Jaguar Health (JAGX) announced that Jaguar family company Napo Pharmaceuticals is providing the company’s novel crofelemer powder for oral solution for treatment of intestinal failure due to microvill...
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID SAN FRANCISCO, CA / A...
Jaguar Health Registration statement: Registration filing
Jaguar Health filed a registration statement on July 16, 2026, providing details about a securities offering with the SEC.
Jaguar Health Registration statement: Registration filing
Jaguar Health filed a registration statement on July 16, 2026, providing details about a securities offering with the SEC.
Jaguar Health files to sell 5.52M shares of voting common stock for holders
06:03 EDT Jaguar Health (JAGX) files to sell 5.52M shares of voting common stock for holders
Jaguar Health files to sell 40.8M shares of voting common stock for holders
06:04 EDT Jaguar Health (JAGX) files to sell 40.8M shares of voting common stock for holders
Jaguar Health provides recap of presentations of crofelemer at ESPGHAN
Jaguar Health (JAGX) provided a recap of presentations of the oral liquid crofelemer as adjunctive therapy in pediatric intestinal failure, IF, patients at the 58th Annual European Society for Pediatr...
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases Near-term milestones for IF program buttressed by continuing groundbreaking results of stu...
Jaguar Health announces conversion of Series O convertible preferred stock
Jaguar Health (JAGX) hereby notifies holders of its Series O Convertible Preferred Stock, par value $0.0001 per share, that the Company has exercised its right to cause the optional conversion…
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases Reminder: Two crofelemer presentations in pediatric intestinal failure pat...
Jaguar Health Transcript: Life Sciences Virtual Investor Forum
A rare disease-focused strategy is driving near-term catalysts, with crofelemer advancing through global trials for intestinal failure and MVID, targeting NDA filing in 2027. Recent clinical data show significant reductions in parenteral support, and major licensing and partnership deals support ongoing innovation.